论文部分内容阅读
观察肝动脉导管灌注CD3AK细胞联合TAE治疗晚期HCC的效果。方法：40例晚期HCC分为两组，实验组20例，采用肝动脉导管灌注CD3AK细胞联合TAE治疗；对照组20例，单纯TAE治疗。并检测两组AFP及T细胞亚群的变化。结果：实验组与对照组有效率分别为45％、30％（P＜0．01），治疗后实验组CD4、CD4／CD8比值明显升高（P＜0．01），而对照组则轻度下降。AFP两组均明显下降，以实验组为著（P＜0．005）。结论：肝动脉导管灌注CD3AK细胞联合TAE治疗晚期HCC，是一种最有希望的方法。
To observe the effect of hepatic artery catheter perfusion of CD3AK cells combined with TAE on advanced HCC. METHODS: Forty patients with advanced HCC were divided into two groups. The experimental group consisted of 20 patients. The patients were treated with hepatic artery catheter perfusion with CD3AK cells combined with TAE. In the control group, 20 patients were treated with TAE alone. The changes of AFP and T cell subsets in the two groups were detected. Results: The effective rates of the experimental group and the control group were 45% and 30% respectively (P<0.01). After treatment, the ratios of CD4 and CD4/CD8 in the experimental group increased significantly (P<0.01), while the control group was lighter. Declined. AFP decreased significantly in both groups, with the experimental group (P<0.005). CONCLUSIONS: Transcatheter arterial infusion of CD3AK cells in combination with TAE for advanced HCC is the most promising method.